Expression of CD10 in Malignant Müllerian Mixed Tumors and Adenosarcomas: An Immunohistochemical Study

Mikami, Yoshiki; Hata, Sakae; Kiyokawa, Takako; Manabe, Toshiaki

doi:10.1097/01.mp.0000026058.33869.db

Cited by 70 publications

(38 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These fi ndings suggest that CD10 has a wide distribution in various cell types, and that its diagnostic usefulness is limited in surgical pathology. However, it has been proposed that CD10 immunostaining is a useful marker in the differential diagnosis of follicular carcinomas [15] , renal cell carcinoma versus adrenocortical carcinoma [2] , clear cell carcinoma involving renal and ovarian tissues [2,7,14] , endometrial stromal tumors [7,10,12] , müllerian system derived tumors [12] , and mesonephric and trophoblastic tumors [7] .…”

Section: Discussionmentioning

confidence: 99%

CD10 Expression in Urothelial Bladder Carcinomas: A Pilot Study

Bircan¹,

Çandir²,

Kapucuoğlu³

et al. 2006

Urol Int

View full text Add to dashboard Cite

Objectives: The aims of this study were to investigate the expression of CD10 in normal bladder tissue and urothelial bladder carcinomas and to clarify its association with histopathological variables. Materials and Methods: A total of 79 urothelial bladder carcinomas were selected from routine archival material. All cases were reevaluated histopathologically and graded according to the World Health Organization (WHO) 1973, WHO/ISUP 1998, and WHO 1999 systems. The TNM system was used for their pathological staging. CD10 immunohistochemical staining was performed in selected slides. Results: Tumoral cases consisted of 74 men (93.7%) and 5 women (6.3%). According to the pathological stage, 25 (31.6%), 33 (41.8%), and 21 (26.6%) cases had pTa, pT1, and pT2–3 carcinomas, respectively. 34 of 79 (43%) urothelial carcinomas and only 1 of 11 (9.1%) nontumoral cases showed positive CD10 immunostaining. It was a cytoplasmic diffuse or granular immunostaining pattern both in nontumoral and tumoral urothelia. There was no statistically significant difference between tumoral and nontumoral cases with respect to CD10 reactivity (p = 0.051), but there was a trend toward significance. In urothelial tumors, there was a significant inverse correlation between pathological stages and CD10 immunoreactivity (p = 0.036, r = –0,237). There was also a statistically significant difference between pTa and pT2–3 urothelial tumors in relation to the CD10 expression (p = 0.034). No association was detected between CD10 expression and grades according to all systems used (p > 0.05). Conclusions: According to our findings, the CD10 expression in noninvasive carcinomas showed a higher level than that in invasive carcinomas, and it is inversely correlated with the pathological stage. CD10 may play an important role in the progression of urothelial bladder carcinomas, and downregulation probably facilitates invasion, especially muscle invasion.

show abstract

Section: Discussionmentioning

confidence: 99%

CD10 Expression in Urothelial Bladder Carcinomas: A Pilot Study

Bircan¹,

Çandir²,

Kapucuoğlu³

et al. 2006

Urol Int

View full text Add to dashboard Cite

show abstract

“…Immunohistochemically, CD10 is considered to be the most commonly recognized positive marker for MA [8][9][10][11][12][13][14]; however, WT-1, ER, and PR are also often…”

Section: Introductionmentioning

confidence: 99%

Targeted genomic analysis of Müllerian adenosarcoma

Howitt

Sholl

Cin

et al. 2014

The Journal of Pathology

View full text Add to dashboard Cite

Müllerian adenosarcoma (MA) is a rare mixed mesenchymal tumour of the female genital tract, composed of malignant stroma and benign-appearing epithelium. Sarcomatous overgrowth (SO) is the only established histological variable associated with higher stage and shorter survival. Specific molecular or immunohistochemistry (IHC) tools for the diagnosis of MA are lacking. Our goal was to study genomic mutations and copy number variations (CNVs) in MA to understand better its pathobiology, and develop specific diagnostic and prognostic tools. DNA was extracted from 20 samples of MA from 18 subjects (12 without SO and 6 with SO), including two in which areas of both typical MA histology and SO were independently tested. Samples were analysed using a targeted next-generation sequencing assay interrogating exonic sequences of 275 cancer genes for mutations and CNVs as well as 91 introns across 30 genes for cancer-associated rearrangements. The mean number of mutations in MA with SO (mean 9.7; range 3-14) did not differ significantly from that in MA without SO (mean 9.6; range 5-16). MA with SO had significantly higher mean numbers of gene-level CNVs (24.6) compared to MA without SO (5; p = 0.0002). The most frequent amplification involved MDM2 and CDK4 (5/18; 28%), accompanied by focal CDK4 and MDM2 and diffuse HMGA2 expression using immunohistochemistry. MYBL1 amplification was seen in 4/18 (22%), predominantly in SO. Alterations in PIK3CA/AKT/PTEN pathway members were seen in 13/18 (72%). Notably, TP53 mutations were uncommon, present in only two cases with SO. Three out of 18 (17%) had mutations in ATRX, all associated with SO. No chromosomal rearrangements were identified. We have identified a number of recurrent genomic alterations in MA, including some associated with SO. Although further investigation of these findings is needed, confirmation of one or more may lead to new mechanistic insights and novel markers for this often difficult-to-diagnose tumour.

show abstract

“…In the female genital tract, CD10 reacts with endocervical and endometrial stromal cells, Wolffian remnants, and luteinized cells as well as with benign and malignant endocervical glandular lesions, endometrial adenocarcinomas, mullerian mixed tumors, endometrial stromal tumors, smooth muscle tumors, Wolffian tumors and sex-cord stromal tumors of the ovary. [39][40][41][42][43][44] Our findings revealed extensive CD10 positivity in all MTsV (13 out of 13). To date, only one other very recent case report has shown CD10 positivity in MTsV.…”

Section: Discussionmentioning

confidence: 97%